| Assay ID | Title | Year | Journal | Article |
|---|
| AID1503327 | Antiviral activity against Enterovirus C Sabin ATCC VR 534 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 2 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503321 | Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 96 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503329 | Antiviral activity against Human herpesvirus 1 KOS ATCC VR 1493 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 3 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503330 | Antiviral activity against Vesicular stomatitis virus Indiana ATCC VR 158 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 2 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503333 | Potency index, ratio of azauridine EC50 to compound EC50 for Yellow fever virus 17D vaccine (Stamaril Pasteur J07B01) | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503315 | Antiviral activity against Yellow fever virus 17D vaccine (Stamaril Pasteur J07B01) infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503314 | Cytotoxicity against golden hamster BHK21 cells assessed as decrease in cell viability after 72 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503323 | Antiviral activity against Reovirus 1 infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503331 | Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503320 | Antiviral activity against Bovine viral diarrhea virus NADL ATCC VR 534 infected in bovine MDBK cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503325 | Antiviral activity against Human enterovirus B Faulkner ATCC VR 185 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 3 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503322 | Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503324 | Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503319 | Cytotoxicity against bovine MDBK cells assessed as decrease in cell viability after 72 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1503328 | Antiviral activity against Vaccinia virus Lister ATCC VR 1549 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 3 days by crystal violet staining-based plaque reduction assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | | | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | | | |
| AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | | | |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | | | |
| AID1745846 | Firefly Luciferase Counterscreen for Inhibitors of ATXN expression | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |